Invivyd Inc (IVVD) - News Archive

Invivyd s Strong Stand Against Evolving COVID-19 Challenges and FDA s Progressive StepsIntroductionAs the landscape of COVID-19 continues to evolve with the emergence of new variants, companies and regulators alike must...

: The SARS-CoV-2 pandemic has been characterized by the virus s ability to mutate, leading to the emergence of new variants that challenge current therapeutic and prophylactic measures. Monoclonal antibodies (mAbs) have...

Invivyd, Inc. a biopharmaceutical company based in Waltham, Massachusetts, recently announced a significant publication in The New England Journal of Medicine (NEJM) that underscores a milestone in public health innovat...

In a recent announcement heralding the changing landscape of SARS-CoV-2 variants, Invivyd, Inc. unveiled significant updates surrounding the Emergency Use Authorization (EUA) for its monoclonal antibody therapy, PEMGARD...

In a proactive move to address the rising cases of COVID-19, Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company dedicated to combating serious viral infections, has confirmed its readiness for the upcoming respir...

On September 4, 2024, Invivyd, Inc. announced the dosing of its first participants in a Phase 1 clinical trial for VYD2311, a next-generation monoclonal antibody (mAb) candidate targeting COVID-19. This development is s...

In a significant announcement on September 3, 2024, Invivyd, Inc. (Nasdaq: IVVD), has reaffirmed its commitment to tackling COVID-19 with promising data showcasing the effectiveness of its neutralizing monoclonal antibo...

Pemivibart by Invivyd for Leukemia: Likelihood of Approval and Impact on Invivyd s Stock PerformanceIn recent news, Invivyd, Inc. (NASDAQ: IVVD), a biopharmaceutical company, has gained attention for its clinical develo...

Invivyd Joins Prestigious Russell 2000 and Russell 3000 Indexes, Solidifying Its Position in the Biopharmaceutical IndustryWALTHAM, Mass., July 1, 2024 - Invivyd, Inc. (Nasdaq: IVVD), a leading biopharmaceutical company...

Invivyd Announces Partnership with FDA for Expedited EUA Pathway for COVID-19 TreatmentInvivyd, a leading biopharmaceutical company focused on combating viral infections, has recently announced its collaboration with th...

WALTHAM, Mass., May 29, 2024 The biopharmaceutical landscape anticipates significant insights as Invivyd, Inc. (Nasdaq: IVVD), a company fervently dedicated to combating serious viral infectious diseases, gears up to pr...

Invivyd Announces Significant Improvement in Projected 2024 Year-End Cash PositionInvivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on protecting individuals from serious viral infectious diseases, has r...

Invivyd Receives HCPCS Reimbursement Codes and FDA Authorization for PEMGARDA: A Breakthrough Prophylaxis Against COVID-19WALTHAM, Mass., March 22, 2024 - Invivyd, Inc. (Nasdaq: IVVD), a renowned biopharmaceutical compa...

In a bid to safeguard the vulnerable population from the detrimental impact of viral infectious diseases, pioneering biopharmaceutical company, Invivyd, Inc. (Nasdaq: IVVD), has taken a significant stride forward with t...

PEMGARDA: The Revolutionary Treatment for COVID-19 Pre-Exposure Prophylaxis (PrEP) in Immunocompromised IndividualsIn a groundbreaking announcement, Invivyd, Inc. has unveiled their latest innovation in the fight agains...